Beta Bionics, Inc. (NASDAQ:BBNX) Insider Sells $15,528.52 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 868 shares of Beta Bionics stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $15,528.52. Following the sale, the insider now directly owns 34,132 shares in the company, valued at $610,621.48. This trade represents a 2.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Beta Bionics Stock Performance

Shares of NASDAQ BBNX traded down $0.47 during midday trading on Friday, hitting $19.08. The company's stock had a trading volume of 583,609 shares, compared to its average volume of 503,190. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $24.50. The business has a fifty day simple moving average of $13.05.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.01).

Institutional Trading of Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio acquired a new stake in shares of Beta Bionics during the first quarter valued at approximately $29,000. Corebridge Financial Inc. acquired a new stake in shares of Beta Bionics during the first quarter valued at approximately $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Beta Bionics during the first quarter valued at approximately $95,000. MetLife Investment Management LLC acquired a new stake in shares of Beta Bionics during the first quarter valued at approximately $102,000. Finally, Deutsche Bank AG acquired a new stake in shares of Beta Bionics during the first quarter valued at approximately $148,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a "neutral" rating and a $20.00 price target on the stock. Leerink Partnrs raised shares of Beta Bionics to a "strong-buy" rating in a research report on Monday, February 24th. Robert W. Baird started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 target price for the company. The Goldman Sachs Group started coverage on shares of Beta Bionics in a research report on Friday, May 30th. They issued a "neutral" rating and a $16.00 target price for the company. Finally, Bank of America started coverage on shares of Beta Bionics in a research report on Monday, February 24th. They issued a "buy" rating for the company. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $23.13.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.